Drug Landscape ›
OXPRENOLOL ›
Regulatory · United States
Marketing authorisation
FDA
Safety signals — FAERS
Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.
Window: 20 April 2025 – 20 April 2026
Total reports: 311
Most-reported reactions
Arthralgia — 32 reports (10.29%) Headache — 32 reports (10.29%) Myalgia — 32 reports (10.29%) Bone Pain — 31 reports (9.97%) Burning Sensation — 31 reports (9.97%) Constipation — 31 reports (9.97%) Muscle Spasms — 31 reports (9.97%) Rhinorrhoea — 31 reports (9.97%) Dyspnoea — 30 reports (9.65%) Pain — 30 reports (9.65%)
Source database →
OXPRENOLOL in other countries
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Frequently asked questions
Is OXPRENOLOL approved in United States?
Yes. FDA has authorised it.
Who is the marketing authorisation holder for OXPRENOLOL in United States?
Marketing authorisation holder not available in our data.